322 related articles for article (PubMed ID: 15565180)
21. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
[TBL] [Abstract][Full Text] [Related]
22. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.
Szentirmai O; Baker CH; Bullain SS; Lin N; Takahashi M; Folkman J; Mulligan RC; Carter BS
J Neurosurg; 2008 May; 108(5):979-88. PubMed ID: 18447716
[TBL] [Abstract][Full Text] [Related]
23. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
[TBL] [Abstract][Full Text] [Related]
24. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
[TBL] [Abstract][Full Text] [Related]
25. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
27. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
30. Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
Liu X; Li J; Tian Y; Xu P; Chen X; Xie K; Qiu Z; Wang Y; Zhang D; Wolf F; Li C; Huang Q
Hum Gene Ther; 2010 Feb; 21(2):157-70. PubMed ID: 19751100
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer.
Kaliberov SA; Kaliberova LN; Stockard CR; Grizzle WE; Buchsbaum DJ
Mol Ther; 2004 Dec; 10(6):1059-70. PubMed ID: 15564138
[TBL] [Abstract][Full Text] [Related]
32. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin.
Chen CT; Lin J; Li Q; Phipps SS; Jakubczak JL; Stewart DA; Skripchenko Y; Forry-Schaudies S; Wood J; Schnell C; Hallenbeck PL
Hum Gene Ther; 2000 Sep; 11(14):1983-96. PubMed ID: 11020798
[TBL] [Abstract][Full Text] [Related]
34. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy.
Guan M; Tripathi V; Zhou X; Popescu NC
Cancer Gene Ther; 2008 Jun; 15(6):371-81. PubMed ID: 18369381
[TBL] [Abstract][Full Text] [Related]
36. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
37. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin.
Tanaka M; Grossman HB
Gene Ther; 2003 Sep; 10(19):1636-42. PubMed ID: 12923562
[TBL] [Abstract][Full Text] [Related]
38. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
Song W; Dong Z; Jin T; Mantellini MG; Núñez G; Nör JE
Cancer Gene Ther; 2008 Oct; 15(10):667-75. PubMed ID: 18566614
[TBL] [Abstract][Full Text] [Related]
39. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts.
Anai S; Goodison S; Shiverick K; Iczkowski K; Tanaka M; Rosser CJ
Hum Gene Ther; 2006 Oct; 17(10):975-84. PubMed ID: 16984224
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
